Literature DB >> 9605982

In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).

R B Moss1, M R Wallace, P Lanza, W Giermakowska, F C Jensen, G Theofan, C Chamberlin, S P Richieri, D J Carlo.   

Abstract

We examined the effect of immune stimulation by a human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) compared to a non-HIV vaccine (influenza) on HIV-1-specific immune responses in HIV-1-seropositive subjects. HIV-1 p24 antigen-stimulated lymphocyte proliferation was not augmented after immunization with the influenza vaccine. In contrast, subjects increased their lymphocyte proliferative responses to p24 antigen after one immunization with HIV-1 immunogen (Remune) (gp120-depleted inactivated HIV-1 in incomplete Freund's adjuvant). Furthermore, p24 antigen-stimulated beta-chemokine production (RANTES, MIP-1alpha, MIP-1beta) was also augmented after immunization with the HIV-1 immunogen but not influenza vaccine. Taken together, these results suggest that in this cohort, HIV-specific immune responses to p24 antigen can be augmented after immunization with an HIV-1 immunogen. The ability to upregulate immune responses to the more conserved core proteins may have important implications in the development of immunotherapeutic interventions for HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605982      PMCID: PMC104515          DOI: 10.1128/CDLI.5.3.308-312.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  20 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

2.  Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses.

Authors:  S K Kundu; D Katzenstein; F T Valentine; C Spino; B Efron; T C Merigan
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-08-01

3.  Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.

Authors:  J F Krowka; D P Stites; S Jain; K S Steimer; C George-Nascimento; A Gyenes; P J Barr; H Hollander; A R Moss; J M Homsy
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases.

Authors:  S M Schnittman; L Fox
Journal:  AIDS Res Hum Retroviruses       Date:  1997-07-01       Impact factor: 2.205

5.  Lymphoproliferative responses to human immunodeficiency virus antigen in asymptomatic intravenous drug abusers and in patients with lymphadenopathy or AIDS.

Authors:  M M Reddy; A Englard; D Brown; E Buimovici-Klien; M H Grieco
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

6.  Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.

Authors:  J M Zarling; J W Eichberg; P A Moran; J McClure; P Sridhar; S L Hu
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

7.  HIV-1-Specific Functional Immune Measurements as Markers of Disease Progression.

Authors:  R.B. Moss; S.P. Richieri; F. Ferre; A.E. Daigle; R. Trauger; G. Theofan; W. Giermakowska; P. Lanza; S. Brostoff; D.J. Carlo; F.C. Jensen
Journal:  J Biomed Sci       Date:  1997 Jul-Aug       Impact factor: 8.410

8.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

9.  Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.

Authors:  R B Moss; W Giermakowska; P Lanza; J L Turner; M R Wallace; F C Jensen; G Theofan; S P Richieri; D J Carlo
Journal:  Viral Immunol       Date:  1997       Impact factor: 2.257

10.  Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.

Authors:  R B Moss; R J Trauger; W K Giermakowska; J L Turner; M R Wallace; F C Jensen; S P Richieri; F Ferre; A E Daigle; C Duffy; G Theofan; D J Carlo
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-04-01
View more
  5 in total

Review 1.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

Review 2.  HIV infection and pathogenesis: what about chemokines?

Authors:  R C Gallo; A Garzino-Demo; A L DeVico
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

3.  Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates.

Authors:  T Lehner; Y Wang; M Cranage; L Tao; E Mitchell; C Bravery; C Doyle; K Pratt; G Hall; M Dennis; L Villinger; L Bergmeier
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

4.  Production and purification of immunologically active core protein p24 from HIV-1 fused to ricin toxin B subunit in E. coli.

Authors:  Alberto J Donayre-Torres; Ernesto Esquivel-Soto; María de Lourdes Gutiérrez-Xicoténcatl; Fernando R Esquivel-Guadarrama; Miguel A Gómez-Lim
Journal:  Virol J       Date:  2009-02-06       Impact factor: 4.099

5.  Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells.

Authors:  Mathias Lichterfeld; Daniel E Kaufmann; Xu G Yu; Stanley K Mui; Marylyn M Addo; Mary N Johnston; Daniel Cohen; Gregory K Robbins; Eunice Pae; Galit Alter; Alysse Wurcel; David Stone; Eric S Rosenberg; Bruce D Walker; Marcus Altfeld
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.